




SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)

RECOMMEND WITH CONFIDENCE— SHINGRIX IS COVERED»

For your patients 50 years and older with commercial insurance plans:



**More than 9 out of 10 are covered,
with average copays just [\$4] or less—
making SHINGRIX cost less than a
[movie ticket].^{1,2,*}**

For your Medicare Part D patients:



**100% of Medicare Part D patients are covered.
In some cases, out-of-pocket costs may apply,
as with most medicines covered by Part D.**

If out-of-pocket costs do apply, for most patients,
the cost is less than \$50.^{1,2,*}

*SOURCE: Managed Markets Insight & Technology, LLC, Database as of [February 2022]. Coverage represents access to reimbursement from a health plan with restrictions appropriate to the Advisory Committee on Immunization Practices (ACIP) recommendation(s) and/or prescribing information, which means no accompanying step edits. Veteran's Affairs (VA) and Indian Health Service (IHS) lives have been omitted when calculating the percentage of lives.

Learn more at SHINGRIXHCP.COM

INDICATION

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

IMPORTANT SAFETY INFORMATION:

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

Please see additional Important Safety Information on the next page and accompanying full [Prescribing Information](https://SHINGRIXHCP.COM), also available at [SHINGRIXHCP.com](https://SHINGRIXHCP.COM)

IMPORTANT SAFETY INFORMATION (CONT'D):

- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see additional Important Safety Information on the previous page and accompanying full [Prescribing Information](#), also available at SHINGRIXHCP.com

References: 1. Managed Markets Insights & Technology, LLC, Database as of [February 2022]. 2. Data on file, GSK.

Trademarks are owned by or licensed to the GSK group of companies.



©2022 GSK or licensor.
SGXEDTL220005 March 2022
Produced in USA.



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)